{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:24:43Z","timestamp":1768677883488,"version":"3.49.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamacardio.2019.4759","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T13:55:03Z","timestamp":1577973303000},"page":"209","source":"Crossref","is-referenced-by-count":23,"title":["Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention"],"prefix":"10.1001","volume":"5","author":[{"given":"Martin B\u00f8dtker","family":"Mortensen","sequence":"first","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Joseph","family":"Blaha","sequence":"additional","affiliation":[{"name":"The John Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"25","key":"hbr190020r1","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"hbr190020r2","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction.","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"hbr190020r3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"hbr190020r4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"hbr190020r5","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"hbr190020r6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"hbr190020r7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"hbr190020r8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease.","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"hbr190020r9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"hbr190020r10","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease.","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"hbr190020r11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"hbr190020r12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.","volume":"380","author":"Bhatt","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"hbr190020r13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/M17-0681","article-title":"Comparison of five major guidelines for statin use in primary prevention in a contemporary general population.","volume":"168","author":"Mortensen","year":"2018","journal-title":"Ann Intern Med"},{"issue":"11","key":"hbr190020r14","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review.","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"hbr190020r15","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/eurheartj\/ehx658","article-title":"External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.","volume":"39","author":"Darmon","year":"2018","journal-title":"Eur Heart J"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2758272\/jamacardiology_mortensen_2020_br_190020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T14:42:16Z","timestamp":1582123336000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2758272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.4759","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}